BioLum Sciences provides highly selective assay kits and custom assay services for preclinical drug discovery and cell biology research. Our custom assay services and core chemiluminescent kits generate meaningful results to accelerate development of much-needed therapies. With a focus on reactive oxygen and nitrogen species (RONS), BioLum's kits are compatible in a variety of specimens including plasma, blood, serum, EBC, and living cells, empowering pharmaceutical developers with tools to develop and personalize treatments for cardiovascular disease, pain, asthma, chronic obstructive pulmonary disease (COPD), pulmonary arterial hypertension (PAH), and others. Along with our research services, we currently offer research kits for NO (nitric oxide), ONOO- (peroxynitrite), and H2O2 (hydrogen peroxide) for drug discovery, efficacy testing, reactivity/activity testing, dose dependency, ADME, formulation optimization, and drug repurposing. With the advent of biomarker analysis for monitoring disease severity and progression, there is a desire to shift towards remote patient monitoring via non-invasive biomarkers to improve treatment plans and lower overall costs on the healthcare system. With a 2-pronged approach, we aim to tranlsate our research kits into clinical IVD devices. Our blood analysis product measures NO (nitric oxide) in the blood using a finger-prick test. This point-of-care test will provide physicians, researchers, and patients a critical gauge of endothelial dysfunction and cardiovascular health. Our breath analysis product, the BioSense AMD (Airway Monitoring Device) for H2O2 (hydrogen peroxide), provides a ‘window into the lung’ by measuring oxidative stress in exhaled breath condensate (EBC). Our test requires no complicated breathing maneuvers, allowing reliable at-home monitoring.
Location: United States, Texas, Dallas
Employees: 1-10
Total raised: $251.9K
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | SWPDC | swpdc.org/ |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 22.12.2021 | Grant | $251.9K | - |
Mentions in press and media 3
| Date | Title | Description |
| 28.05.2025 | Inhalation Sciences Expands Horizons: Strategic Moves in the U.S. Market | Inhalation Sciences AB (ISAB) is making waves in the world of respiratory research. The company, based in Stockholm, has recently signed a strategic agreement with BioLum Sciences, a U.S.-based firm specializing in inhalation diagnostics. T... |
| 28.05.2025 | Inhalation Sciences: Breathing New Life into Respiratory Research | Inhalation Sciences AB (ISAB) is making waves in the world of respiratory research. The company, based in Sweden, is on a mission to transform how inhalation studies are conducted. With its innovative technologies, ISAB is poised to reshape... |
| 22.05.2025 | Inhalation Sciences Signs Strategic Agreement with U.S.-based BioLum Sciences, expanding U.S. Presence & Commercial Reach to Advance In Vitro Respiratory Research | Inhalation Sciences Signs Strategic Agreement with U.S.-based BioLum Sciences, expanding U.S. Presence & Commercial Reach to Advance In Vitro Respiratory Research Thu, May 22, 2025 08:30 CET Report this content Stockholm, May 22, 2025 -... |